5 results for “Houston”
Houston’s BMS win will spark competing Texas incentive bids as other pharma firms hunt flexible ADC and biologics capacity.
This is a concrete reshoring-and-scale signal: big pharma is placing large, flexible capacity bets in the U.S. to support late-stage development through launch, with Texas positioning itself as a life-sciences manufacturing hub.
Texas will market the BMS win to lure another top-10 pharma manufacturing project into Houston’s Generation Park.
A multi-modality plant signals where big pharma is placing long-horizon capacity bets—especially for biologics and ADCs—while states compete with incentives.
Texas will market BMS’s Generation Park win to lure another top-10 pharma plant announcement before 2027 construction ramps.
A top-tier pharma manufacturer is placing flexible, multi-modality capacity in Texas—an industrial bet on domestic supply resilience and next-generation modalities like ADCs.
Flock camera deployments will face sharper public pushback as wrongful-stop stories fuel calls for tighter limits.
This is a fast-growing trust story around AI-adjacent surveillance infrastructure. The combination of alleged misuse, wrongful stops, and official defense makes it highly shareable and likely to keep expanding.
Cities will face louder demands to audit Flock systems after more wrongful stops and privacy protests.
This is a classic adoption-versus-accountability story. The technology is spreading, but the public conversation is shifting from crime-solving utility to error rates, civil liberties and police verification failures.
You're all caught up · last 5 days